Efficacy

Efficacy of Stelara (Ustekinumab) in Treating Psoriasis

Stelara (ustekinumab) is a biologic medication approved by the FDA for the treatment of moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy. Ustekinumab works by targeting interleukin-12 (IL-12) and interleukin-23 (IL-23), two proteins that play a key role in the inflammatory processes associated with psoriasis. Clinical trials have demonstrated that Stelara can lead to significant skin clearance in many patients. In these studies, patients treated with Stelara often achieved a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) score, which is a measure of the severity and extent of psoriasis, indicating a substantial improvement in the disease.

The efficacy of Stelara was further highlighted in long-term studies, where a significant number of patients maintained their PASI 75 response with continued treatment. Moreover, some patients even achieved PASI 90 and PASI 100 responses, representing 90% and 100% improvement in psoriasis, respectively. The treatment has been shown to improve the quality of life for many patients, reducing the physical and psychological burden of the disease.

Efficacy of Sotyktu (Deucravacitinib) in Treating Psoriasis

Sotyktu (deucravacitinib) is a novel oral medication that has shown promise in the treatment of moderate to severe plaque psoriasis. As a selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib works by modulating the immune response, which is dysregulated in psoriasis. In clinical trials, Sotyktu was found to be effective in achieving skin clearance. Patients treated with deucravacitinib demonstrated a significant reduction in PASI scores compared to those who received placebo, with many participants reaching PASI 75, indicating a 75% reduction in the severity and extent of their psoriasis.

Notably, the efficacy of Sotyktu in psoriasis treatment was sustained over time, with a significant number of patients maintaining their PASI responses throughout the trial periods. The medication was generally well-tolerated, and the convenience of an oral administration route is a potential advantage over injectable treatments. Sotyktu represents a new class of medication for psoriasis, offering an alternative to patients who may not respond to or tolerate other systemic therapies.